In 2023, we also completed several initiatives to improve our credit profile and de-risk our capital structure. As you know, we divested our travel health business, generating up to $380 million of proceeds, extended the maturity of our secured credit facility to May 2025, implemented actions to save over $160 million of annualized operating expense, and announced a strategic shift to focus on our products business.

Mar 6, 2024 / receipt, needs a key / Rich Lindahl, CFO | earnings call 2024-03-06 | transcript 08fc61fa-6343-475b-9c5c-4c1b423dce19 | chars 16362-16781 | segment 16

Throughout 2023, we've taken significant steps to strengthen our financial position and de-risk the business. We have executed the travel health divestiture, implemented actions to save over $160 million of annualized operating expense, and announced a strategic shift to de-emphasize our CDMO business as a source of growth.

Nov 2, 2023 / receipt, needs a key / Rich Lindahl, EVP and Chief Financial Officer | earnings call 2023-11-02 | transcript a3c43158-a69b-428b-88a3-5dd16d3371ed | chars 16674-16999 | segment 16

First, as Bob noted, we anticipate closing on the divestiture of the travel health business in the second quarter. which will provide an infusion of upfront cash while furthering our stated objective of sharpening our strategic focus. The impact of the sale is now incorporated into our updated guidance for 2023 and enables us to better align our cost structure with our current revenue trajectory.

May 9, 2023 / receipt, needs a key / Rich Lindahl, CFO | earnings call 2023-05-09 | transcript 89444fcb-fd56-4aab-b42e-92dd60dd460d | chars 13845-14244 | segment 13

First, we expect the sale of our travel health business to Bavarian Nordic to close as planned in the second quarter of this year. Upon closing, the deal will provide an upfront cash payment of approximately $270 million and a potential additional $110 million in sales and development-based milestones.

May 9, 2023 / receipt, needs a key / Bob Kramer, CEO | earnings call 2023-05-09 | transcript 89444fcb-fd56-4aab-b42e-92dd60dd460d | chars 4106-4409 | segment 4

smallpox MCM sales of $235 to $255 million, other product sales of $165 to $185 million, CDMO services revenues of $115 to $135 million, adjusted net loss of $30 to $80 million, adjusted EBITDA of $75 to $125 million, and adjusted gross margin 41 to 44 percent this full year 2023 forecast reflects the following key considerations it excludes the potential impact of the sale of our travel health business we will update our guidance accordingly after the transaction closes which is anticipated in the second quarter it assumes the over-the-counter launch of Narcan by the end of the summer with continued strong demand in the US public interest channel as well as continuing demand in Canada continued procurement and delivery of anthrax, smallpox, and other medical countermeasure products to the U.S. and allied governments, and continued rebaselining of the CDMO services business overall and the impact of reduced production output from the Camden facility.

Feb 27, 2023 / receipt, needs a key / Rich Lindahl, CFO | earnings call 2023-02-27 | transcript 802ffaca-7841-437c-8d8f-e7f6a00e9f55 | chars 20696-21660 | segment 20

The position elimination and other actions we announced earlier in the year, in combination with the sale of our travel health business, will better align our cost structure with our revenue trajectory as we continue to strengthen quality and compliance and operationalize the network investments made over the past three years.

Feb 27, 2023 / receipt, needs a key / Rich Lindahl, CFO | earnings call 2023-02-27 | transcript 802ffaca-7841-437c-8d8f-e7f6a00e9f55 | chars 12044-12372 | segment 12

Also earlier this month, we announced an agreement to sell our travel health business to Bavaria Nordic, which accomplishes two goals. It will help ensure that Vaxcora and VivoTeeth remain available to international travelers and other patients who need them.

Feb 27, 2023 / receipt, needs a key / Bob Cramer, CEO | earnings call 2023-02-27 | transcript 802ffaca-7841-437c-8d8f-e7f6a00e9f55 | chars 5046-5305 | segment 5

Also within commercial products business, the steady return of global travel has resulted in a stronger than anticipated demand for our typhoid vaccine, Divotif. We're also in the process of ramping up the supply chain for our cholera vaccine, Vaxcora, for the U.S. market and introducing it into select European markets. We're targeting early Q1 of 2023 to make supply available.

Nov 8, 2022 / receipt, needs a key / Bob Cramer, CEO | earnings call 2022-11-08 | transcript 04b23cb7-beca-4fa3-8e13-1a17c0ce5e10 | chars 7823-8203 | segment 8

As we're now seeing a return to global travel, we've restarted sales of VivoTeef in North America and in Europe and are in the process of relaunching VaxCora in the United States and launching Vaxcora in Europe.

Aug 1, 2022 / receipt, needs a key / Bob Cramer, CEO | earnings call 2022-08-01 | transcript 64ac572b-7019-4e0f-8a00-d516dda5fb07 | chars 8716-8927 | segment 8

I think at a macro level, we've been evaluating when the right time to relaunch travel health is, and that's really been the focus. I think the The ACIP recommendation is, I think, more, I'll say, some positive momentum that that's going to return, and those products are going to be needed. And so it just came through and was just announced. I don't think we've had kind of a new take on the market sizing, especially in the U.S. traveler, but I think the take-home message right now is we're excited to relaunch that travel health business once we get past this pandemic.

Feb 24, 2022 / receipt, needs a key / Adam, other | earnings call 2022-02-24 | transcript edffc30b-ebd3-4c44-846a-9cc642d7bc4f | chars 34966-35540 | segment 35

As we look forward to international travel beginning to resume, we plan to restart the business with the relaunch of VivoTeef and Vexcora in key markets later in 2022.

Feb 24, 2022 / receipt, needs a key / Jennifer Fox, other | earnings call 2022-02-24 | transcript edffc30b-ebd3-4c44-846a-9cc642d7bc4f | chars 9170-9337 | segment 8

Doug's portfolio includes Narcan nasal spray, travel vaccines, and other similar customer-facing products.

Nov 4, 2021 / receipt, needs a key / Bob Cramer, CEO | earnings call 2021-11-04 | transcript d20bc253-feca-427f-8f73-25e2c8f0433a | chars 9811-9917 | segment 9